Status:
UNKNOWN
Letrozole in Tubal Ectopic Pregnancy
Lead Sponsor:
Queen Mary Hospital, Hong Kong
Collaborating Sponsors:
Kwong Wah Hospital
Princess Margaret Hospital, Hong Kong
Conditions:
Tubal Pregnancy
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
This is a multi-centred randomized controlled trial on the addition of letrozole in the medical management of tubal ectopic pregnancies. Tubal ectopic pregnancies are abnormal pregnancies in the Fall...
Detailed Description
Tubal ectopic pregnancies occur in around 1-2% of all pregnancies. Traditionally, surgery with salpingectomy was the mainstay of treatment; however, it comes with anaesthetic and operatives risks in a...
Eligibility Criteria
Inclusion
- Presence of heterogenous adnexal mass on USG suggestive of tubal ectopic pregnancy with hCG level \>=1500 IU/L and \<= 5000 IU/L
- Absence of fetal heart pulsation
- Mean diameter of adnexal mass \<= 3.5cm
- Haemodynamically stable
- No significant abdominal pain
Exclusion
- Presence of significant amount of free fluid in pelvis
- Allergic to MTX
- Deranged liver function test (AST/ ALT or GGT \>= 2 upper limit of normal)
- Deranged renal function test (eGFR \<= 45ml/min)
- Heterotopic pregnancies
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2025
Estimated Enrollment :
214 Patients enrolled
Trial Details
Trial ID
NCT04341545
Start Date
December 1 2020
End Date
March 31 2025
Last Update
April 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Obstetrics and Gynaecology, Queen Mary Hospital
Hong Kong, Hong Kong